Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report)’s share price gapped down before the market opened on Monday . The stock had previously closed at $42.39, but opened at $40.44. Cogent Biosciences shares last traded at $41.0360, with a volume of 454,016 shares traded.

COGT has been the topic of a number of analyst reports. HC Wainwright upped their price target on Cogent Biosciences to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Wedbush reissued an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a report on Friday, May 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a report on Wednesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $45.90.

View Our Latest Research Report on Cogent Biosciences

The stock has a market capitalization of $7.10 billion, a price-to-earnings ratio of -19.15 and a beta of 0.38. The company has a current ratio of 15.14, a quick ratio of 15.14 and a debt-to-equity ratio of 0.41. The stock has a fifty day moving average of $37.39 and a two-hundred day moving average of $36.65.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The technology company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.01. As a group, equities research analysts forecast that Cogent Biosciences, Inc. will post -2.26 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in COGT. AQR Capital Management LLC increased its position in Cogent Biosciences by 482.6% in the first quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company’s stock worth $963,000 after purchasing an additional 133,174 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Cogent Biosciences by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company’s stock valued at $377,000 after purchasing an additional 3,693 shares during the period. Goldman Sachs Group Inc. lifted its position in Cogent Biosciences by 14.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company’s stock valued at $5,924,000 after purchasing an additional 124,069 shares during the period. Jane Street Group LLC boosted its stake in shares of Cogent Biosciences by 66.2% in the 1st quarter. Jane Street Group LLC now owns 123,822 shares of the technology company’s stock valued at $742,000 after purchasing an additional 49,338 shares during the last quarter. Finally, Strs Ohio acquired a new stake in shares of Cogent Biosciences during the 1st quarter worth approximately $36,000.

(Get Free Report)

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

• Five stocks we like better than Cogent Biosciences
• These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
• First Solar’s Profit Engine Faces a New Policy Test in Washington
• 5 Stocks the Market Rewarded After Strong Earnings Results
• Is Wingstop’s Growth Story Losing Steam?

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

PIMCO 15+ Year U.S. TIPS Index Exchange-Traded Fund (NYSEARCA:LTPZ) Sees Unusually-High Trading Volume – Should You Buy?

National Australia Bank (OTCMKTS:NABZY) Shares Gap Down – Should You Sell?